mercredi 21 octobre 2015

Neovacs : Jason McCarthy annonce un objectif de cours strastosphérique

Sometimes a rifle shot can only stop a single target and is not enough to stop a herd. Similarly, a single monoclonal antibody (MAb) can only stop one arm of the immune system. You need the power of a shotgun to stop multiple branches of autoimmune diseases in its tracks. Neovacs' Kinoid vaccine technology is a polyclonal antibody ("shotgun") approach to autoimmune diseases, including systemic lupus erythematosis (SLE), or lupus. 

• The key to treating SLE is the cytokine INFα (interferon alpha), but this comes in 13 flavors. MAbs may halt a few INFαs, leaving the others to compensate. A shotgun approach, however, covers all 13 isotypes. INF-Kinoids (INF-K) are the SLE shotgun. Phase I/II data has shown that INF-K neutralizes all INFα and shuts off INFα-controlled inflammatory genes. A phase IIb proof of concept (POC) study (n=166) is underway in Europe and phase II studies in the U.S. and China should initiate in early 2016.

Zacks: Pharming Group Receives Consensus Rating of “Strong Buy” from Analysts

Pharming Group (NASDAQ:PHGUF) has received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

Analysts have set a 12 month consensus target price of $3.00 for the company, according to Zacks. Zacks has also assigned Pharming Group an industry rank of 92 out of 265 based on the ratings given to its competitors.